The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary results of single arm phase 2 trial of brigatinib in patients (pts) with progression disease (PD) after next-generation (NG) anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in ALK + non-small cell lung cancer (NSCLC).
 
Tom Stinchcombe
Consulting or Advisory Role - AstraZeneca; G1 Therapeutics; G1 Therapeutics; Genentech/Roche; Novartis; Regeneron; Takeda
Research Funding - AstraZeneca (Inst); Blueprint Medicines (Inst); Genentech/Roche (Inst); Merck (Inst); Takeda (Inst)
 
Robert Charles Doebele
Stock and Other Ownership Interests - Rain Therapeutics
Consulting or Advisory Role - AstraZeneca; Bayer; GreenPeptide; Ignyta; OncoMed; Rain Therapeutics; Roche/Genentech; Takeda
Research Funding - Ignyta (Inst)
Patents, Royalties, Other Intellectual Property - Licensing fees for biologic materials from Genentech (Inst); Licensing fees for patent from Rain Therapeutics; Licensing Fees from Abbott Molecular for Patent PCT/US2013/057495; Licensing fees from Ignyta for biologic materials (Inst)
Travel, Accommodations, Expenses - Ignyta; Rain Therapeutics; Roche/Genentech
 
Xiaofei F. Wang
No Relationships to Disclose
 
David E. Gerber
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - Bristol-Myers Squibb; Samsung Bioepis
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - ArQule (Inst); BerGenBio (Inst); ImClone Systems (Inst); Immunogen (Inst); Karyopharm Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Decision Support in Medicine from the Clinical Decision Support--Oncology on-line program.; Royalties from Oxford University Press from two books.
Travel, Accommodations, Expenses - ArQule; Bristol-Myers Squibb; Lilly; Lilly
 
Leora Horn
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genentech; Incyte; Janssen; Lilly; Merck; Tesaro; Xcovery
Research Funding - Boehringer Ingelheim (Inst); Xcovery (Inst)
Other Relationship - Boehringer Ingelheim; Bristol-Myers Squibb
 
D. Ross Camidge
Honoraria - AstraZeneca; bio-thera; Daiichi Sankyo; G1 therapeutics; Genoptix; Hansoh; Ignyta; Lycera; Mersana; Revolution Medicines; Roche; takeda
Research Funding - Takeda